Japan's Shionogi Patent Data At Center Of U.S. Dispute Over Crestor
This article was originally published in PharmAsia News
Executive Summary
Alleged omissions by Japan's Shionogi when it submitted patent information lies at the heart of a major U.S. patent dispute over the blockbuster cholesterol drug Crestor (rosuvastatin)